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Alzheimer's disease risk locus 7
D10S1423e longitudinal studies have revealed an interaction of the anonymous D10S1423
234 bp allele with the APOE4 allele in determining the age-speciﬁc risk of Alzheimer's disease (AD). The
D10S1423 polymorphism resides within intron 10 of open reading frame C10orf112, whose predicted product
resembles a low-density lipoprotein receptor (NCBI Build 35.1). These observations suggest that the
D10S1423 234 bp allele may be in linkage disequilibrium with a C10orf112 gene variant whose product
interacts with the apoE4 lipoprotein. Our initial exploration of this hypothesis focused on validating the
C10orf112 gene model. RT-PCR ampliﬁcation from human hippocampal mRNA conﬁrmed that 34 of the
predicted 39 exons of C10orf112 were expressed in this brain region. Northern blots revealed 1.2 kb and
3.2 kb mRNA species that hybridize to a cDNA probe consisting of contiguous exons 23–26. Expression of
these C10orf112 mRNA species was limited to a subset of brain regions and heart tissue.
© 2008 Elsevier Inc. All rights reserved.IntroductionTypical, later-onset forms of Alzheimer's disease (AD) appear to be
inﬂuenced by multiple susceptibility loci, combinations of which
contribute to the development of this disorder [1]. We previously
reported the results of a systematic survey of the human genome for
the identiﬁcation of highly informative DNA polymorphisms (SSTRPs)
that target new AD risk genes [2]. In addition to the APOE locus, our
survey detected ﬁve new candidate susceptibility loci for AD,
including D10S1423. An association of the D10S1423 234 bp allele
with AD has been reported in three independent samples of AD cases
and controls (Boston, Pittsburgh, Bonn) [2–4]. Data from our case-
control studies suggest a strong synergistic interaction between the
D10S1423 234 bp and APOE E4 risk alleles (234 bp carrier: odds
ratio=2.5, 95% conﬁdence interval=1.4 to 4.5; E4 carrier: odds
ratio=8.3, 95% conﬁdence interval=4.3 to 15.8; both alleles: odds
ratio=23.1, 95% conﬁdence interval=5.3 to 99.5). Patients with
autopsy-conﬁrmed AD who carry the D10S1423 234 bp allele have
also been reported to manifest substantially lower levels of cortical
dopamine and relative preservation of cortical norepinephrine levels
compared to noncarriers, a neurochemical ﬁnding that further
supports a role for this anonymous genotype in the pathophysiology
of AD [5].
These results have been conﬁrmed by a prospective, longitudinal,
double-blind assessment of the age-speciﬁc risk of AD encountered byra Street Pittsburgh, PA 15213.
l rights reserved.325 asymptomatic ﬁrst-degree relatives of AD probands who carried
the D10S1423 234 bp allele, the APOE E4 allele, or both, after 11.5 years
of systematic follow-up [4]. A total of 18 incident cases of AD were
detected during the ﬁrst 3379 subject-years of this longitudinal study.
The effects of carrying either or both of the D10S1423 234 bp and
APOE E4 alleles on the age-speciﬁc risk of developing AD were
determined using Kaplan–Meier survival analysis [6–8]. The age-
speciﬁc risk of developing AD was the greatest for individuals who
carried both alleles (Mantel–Cox statistic=20.12, df=3, p=0.0002;
Breslow statistic=13.36, df=3, p=0.004). Cox proportional hazards
models were developed to estimate the risk ratios for each genotype,
controlling for the potential effects of age at recruitment, sex, and
years of education [6–8]. In the resulting best ﬁtting model, only
individuals who carried both risk alleles exhibited a risk ratio that
differed signiﬁcantly from 1 (risk ratio=16.2, p=0.008, 95% conﬁdence
interval=2.1 to 128.3). In 2001, McKusick named the AD risk locus
identiﬁed by the D10S1423 polymorphism AD7 in Online Mendelian
Inheritance in Man [9].
The molecular mechanism for the interaction of the anonymous
D10S1423 234 bp allele and the APOE4 allele that inﬂuences the age-
speciﬁc risk of AD is unknown. As described in the National Center for
Biotechnology Information human genome database (NCBI Build 35.1;
http://www.ncbi.nlm.nih.gov/), the D10S1423 SSTRP resides within
intron 10 of predicted open reading frame C10orf112. At its location
deep within intron 10, it is unlikely that the D10S1423 SSTRP would
directly affect the expression or properties of the predicted protein
product of C10orf112. The C10orf112 genemodel includes 39 predicted
exons that encode seven low-density lipoprotein (LDL) receptor class a
domains that mediate binding of LDL receptors to lipoproteins, as well
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receptors. These observations raise the possibility that the D10S1423
234 bp allele may be in linkage disequilibrium with a regulatory or
structural C10orf112 gene variant whose product interacts with the
apoE4 lipoprotein to increase the age-speciﬁc risk of AD. To initially
explore this hypothesis, we determined whether the predicted
C10orf112 exons were expressed in human brain tissue, the size(s)
of the mRNA species encoded by C10orf112, and its tissue-speciﬁc
expression.
Results
Description of C10orf112
Salient features of the predicted open reading frame C10orf112
were derived from the NCBI database and are presented in Table 1
(http://www.ncbi.nlm.nih.gov/; Build 35.1). This model describes a
large gene containing 39 exons and 38 introns, totalling 712,720 bps.
The 39 exons total 6885 bps that are sufﬁcient to encode a protein
containing 2295 amino acids. As shown in Table 1, six of the predicted
exons encode a total of seven LDL-receptor class a domains. Typical
LDL receptors include seven such domains that are tandemly repeatedTable 1
Description of C10orf112
Exon Gene numbering Exon Intron Tran
num
Start Stop Size (bp) Size (bp) Start
1 1 45 45 321 1
2 365 461 97 19,418 46
3 19,878 19,979 102 932 143
4 20,910 21,056 147 3552 245
5 24,607 24,773 167 3240 392
6 28,012 28,145 134 1944 559
7 30,088 30,142 55 101 693
8 30,242 30,334 93 2627 748
9 32,960 33,167 208 9418 841
10 42,584 42,730 147 8732 1049
11 51,461 51,558 98 10,466 1196
12 62,023 62,196 174 9399 1294
13 71,594 71,714 121 28,401 1468
14 100,114 100,266 153 429 1589
15 100,694 100,799 106 486 1742
16 101,284 101,651 368 4004 1848
17 105,654 106,066 413 48,005 2216
18 154,070 154,157 88 22,277 2629
19 176,433 176,609 177 2797 2717
20 179,405 179,567 163 40,769 2894
21 220,335 220,491 157 3459 3057
22 223,949 224,083 135 3673 3214
23 227,755 227,968 214 16190 3349
24 244,157 244,404 248 3989 3563
25 248,392 248,683 292 35,232 3811
26 283,914 284,159 246 1411 4103
27 285,569 285,748 180 91 4349
28 285,838 285,995 158 60,699 4529
29 346,693 346,876 184 25,610 4687
30 372,485 372,566 82 12,781 4871
31 385,346 385,497 152 2407 4953
32 387,903 388,011 109 6802 5105
33 394,812 395,032 221 32,549 5214
34 427,580 427,737 158 36,152 5435
35 463,888 464,089 202 27,492 5593
36 491,580 491,843 264 12,321 5795
37 504,163 504,288 126 207,652 6059
38 711,939 712,048 110 83 6185
39 712,130 712,720 591 6295
Total: 6885
LDLR a; Low Density Lipoprotein Receptor Class A domain. MAM; an extracellular domain
receptors. The midpoint of the PCR product used in our previous studies [1,3,4] to genotype t
45,472, within predicted intron 10.within the amino terminal region of the receptor andmediate binding
to lipoproteins. The predicted amino acid sequence of C10orf112 also
includes 9 MAM domains that appear in meprin, A5, receptor protein
tyrosine phosphatase mu, as well as other cell surface receptors, and
participate in cell–cell interactions. The midpoint of the PCR product
used in our previous studies [2,4,5] to genotype the D10S1423 SSTRP is
located at gene position 45,472, within predicted intron 10.
Expression of C10orf112 exons in human brain
Reverse transcription PCR (RT-PCR) was performed using RNA
isolated from human hippocampus to determine whether the
predicted C10orf112 exons were expressed in human brain. Hippo-
campal RNA was used because the hippocampus undergoes early,
characteristic, and extensive degenerative changes that contribute to
memory and learning impairments that are cardinal clinical features
of AD. As a ﬁrst step, cDNAwas synthesized from hippocampal RNA by
extension of oligo(dT)20 primers with reverse transcriptase. Following
digestion of the residual RNA, the ﬁrst strand cDNA was used as
template for PCR that was performed using the primer pairs described
in the Materials and methods. Primer pairs for β-actin were included
as a positive control. Substitution of the human hippocampal RNA forscript
bering
Amino acid range Domains
(amino acid range)
Stop Start Stop LDLR a MAM
45 1 15
142 16 47
244 48 81
391 82 130 86——>
558 131 186 b—176
692 187 231
747 232 249
840 250 280
1048 281 349 313–345
1195 350 398 355- –>
1293 399 431 b——————>
1467 432 489 b——————>
1588 490 529 b—511
1741 530 580 533—>
1847 581 616 b——————>
2215 617 738 706–738 b—690
2628 739 876 744- –>
2716 877 905 b—899
2893 906 964 929–964
3056 965 1019 969- –>
3213 1020 1071 b——————>
3348 1072 1116 b——————>
3562 1117 1187 1151–1182 b–1143
3810 1188 1270 1194–>
4102 1271 1367 b–1348
4348 1368 1449 1370–1404 1408–1444
4528 1450 1509 1495–>
4686 1510 1562 b———— –>
4870 1563 1623 b–1618
4952 1624 1651
5104 1652 1701
5213 1702 1738
5434 1739 1811 1767–>
5592 1812 1864 b——————>
5794 1865 1931 b–1928
6058 1932 2019 1941–1976
1985–2019
6184 2020 2061
6294 2062 2098
6885 2099 2295
in meprin, A5, receptor protein tyrosine phosphatase mu found in many membrane
he D10S1423 simple sequence tandem repeat polymorphism is located at gene position
Fig. 2. Electropherogram of RT-PCR products from ampliﬁcation of predicted exons 23
(lane 1), 26 (lane 2), and the contiguous exons 23 through 26 (lane 3), using cDNA
template prepared from human hippocampus total RNA. The methods employed for RT-
PCR, agarose electrophoresis, and visualization of RT-PCR products are described in the
Materials and methods. Primer pairs are listed in Table 1. The RT-PCR ampliﬁcation of
contiguous exons 23 through 26 was performed using the forward primer within exon
23 and the reverse primer within exon 26, resulting in a product of the predicted size
(946 bp, lane 3). Substitution of genomic DNA for the cDNA template in the last
experiment resulted in no ampliﬁcation due to the size of the intervening introns, as
expected (lane 4). RT-PCR products for β-actin served as a positive (+) control. RT-PCR
products were ﬂanked by molecular weight standards (MW, 100 bp ladder).
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(blank gels not shown), conﬁrming the absence of contaminating
genomic DNA that could confound the RT-PCR results.
As shown in Fig. 1, the results of RT-PCR revealed that 34 of the 39
predicted exons in the C10orf112 model are expressed in human
hippocampus. There was no evidence of expression of exons 1, 7, 22,
25, or 27. Exclusion of these ﬁve exons would result in a reduction of
the predicted mRNA transcript length to 6175 bps, and a predicted
protein product that retained all 7 LDL-receptor class a domains and 6
of the 9 MAM domains. PCR ampliﬁcation of all ﬁve missing exons
from the ﬁrst-strand cDNA was reattempted with at least one
additional primer pair without success. Furthermore, the successful
ampliﬁcation of exon 2 from the ﬁrst strand cDNA preparation
excluded incomplete reverse transcription of the C10orf112 mRNA as
the basis for the failed ampliﬁcation of exons 7, 22, 25 and 27.
Preparation of cDNA sequence for interrogating northern blots
A cDNA probe consisting of exons 23 through 26 was synthesized
to interrogate northern blots of size fractionatedmRNA to characterize
the predicted C10orf112 mRNA and its tissue speciﬁc expression. This
cDNA sequence was chosen because it covered multiple contiguous
exons of the predicted transcript without being unwieldy (sum of
exons 23 through 26=946). Its position within the midportion of the
predicted gene allowed for revisions to occur in the endpoints of the
C10orf112 model without confounding the results of the northernFig. 1. Electropherograms of RT-PCR products resulting from ampliﬁcation of predicted
C10orf112 exons using cDNA template prepared from human hippocampus total RNA.
Themethods employed for RT-PCR, agarose electrophoresis, and visualization of RT-PCR
products are described in the Materials and methods. Primer pairs are listed in Table 1.
Each of the three electropherograms includes thirteen numbered lanes corresponding
to the RT-PCR products for the predicted exon of the same number, followed by the RT-
PCR products for β-actin as a positive (+) control. Substitution of the original human
hippocampus total RNA for the ﬁrst strand cDNA product as template resulted in no
ampliﬁcation (blank gels not shown). RT-PCR products were ﬂanked by molecular
weight standards (MW, 100 bp ladder).blots by hybridizing to mRNA species from adjacent genes. Although
exons 23 and 26 encode LDL-receptor class a domains, this was not
expected to result in nonspeciﬁc hybridization to LDL receptor mRNAs
because the domains are conserved at the amino acid level, not at the
nucleotide sequence level. As shown in Fig. 2, the RT-PCR ampliﬁca-
tion of the predicted contiguous exons 23 through 26 was performed
using cDNA template prepared from human hippocampus total RNA.
Ampliﬁcation of contiguous exons 23 through 26was performed using
the forward primer within exon 23 and the reverse primer within
exon 26, resulting in a product of the predicted size (lane 3).
Substitution of genomic brain DNA for the cDNA template in the last
experiment resulted in no ampliﬁcation, as expected from the size of
intervening introns (lane 4). These ﬁndings are consistent with the
prediction that exons 23 though 26 are sequentially encoded in
C10orf112 mRNA from the hippocampus.Fig. 3. Autoradiogram of northern blot of size fractionated human brain poly A+ mRNA
interrogated by a probe consisting of contiguous exons 23 through 26. The probe was
produced by RT-PCR ampliﬁcation of contiguous exons 23 through 26 using the forward
primer within exon 23 and the reverse primer within exon 26 (see Fig. 2, lane3). The
methods employed for preparing and probing the northern blot are described in the
Materials and methods. The sizes of mRNA species shown in the nothern blot were
extrapolated from molecular weight standards included in the electropherogram. The
radiolabeled probe hybridized to a prominent 1.2 kbmRNA species and a less prominent
3.2 kb mRNA species.
Fig. 4. Autoradiogram of high-throughput northern blot of size fractionated poly A+mRNA from human tissues interrogated by a probe consisting of contiguous exons 23 through 26.
The probe was produced by RT-PCR ampliﬁcation of contiguous exons 23 through 26 using the forward primer within exon 23 and the reverse primer within exon 26 (see Fig. 2,
lane3). In addition to placenta (positive control), the probe predominantly hybridized tomRNA from three brain regions (hippocampus, occipital lobe, parietal lobe). Hybridization to
heart mRNA also exceeded background levels. Descriptions of the tissue sources of mRNA fractionated in each lane are indicated across the top of the blot. The size ranges (kb) of the
fractionated mRNAs are shown for alternate rows.
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An autoradiogram of a northern blot of size fractionated human
brain poly A+mRNA interrogated by the C10orf112 probe consisting of
contiguous exons 23 through 26 (Fig. 2, lane 3) is shown in Fig. 3. The
sizes of mRNA species shown in the northern blot were extrapolated
from molecular weight standards included in the electropherogram.
The radiolabeled probe hybridized to a prominent 1.2 kb mRNA
species and a less prominent 3.2 kb mRNA species.
Tissue speciﬁc expression of C10orf112
An autoradiogram of a high-throughput northern blot of size
fractionated poly A+ mRNA from human tissues was interrogated by
the same C10orf112 probe consisting of contiguous exons 23 through 26
(Fig. 2, lane 3). As shown in Fig. 4, the probe predominantly hybridized
to mRNA from three brain regions including hippocampus, occipital
lobe, and parietal lobe. Hybridization to heart mRNA also exceeded
background levels. In contrast, hybridization of the probe tomRNA from
several other brain regions, including the frontal and temporal lobes and
the cerebellum, and numerous other tissues did not exceed background
levels. Placental mRNA served as a positive control. The sizes of the
mRNAs detected were in the 1.2 kb to 3.2 kb range detected in Fig. 3.
Discussion
The principal ﬁnding of this study is that nearly all (34 of 39) of the
predicted exons of the C10orf112 model are selectively expressed in
human brain regions. Like LDL receptors, the C10orf112 gene includes
seven LDL-receptor class a domains, suggesting that its biological
functions include binding to apolipoproteins. The presence of six
encoded MAM domains, a common feature of membrane receptors, is
consistent with the possibility that the C10orf112 gene product may
reside at an internal or external cell membrane location with the
opportunity to interact with apolipoproteins. These observations raise
the possibility that the D10S1423 234 bp allele may be in linkage
disequilibrium with a regulatory or structural C10orf112 gene variant
whose product interacts with apoE4 to increase the age-speciﬁc risk of
AD. This hypothesis suggests an initial molecular mechanism for the
elevated age-speciﬁc risk of AD among individuals who carry both the
D10S1423 234 bp allele and the APOE4 allele. While our results also
indicated modest expression of C10orf112 exons in heart tissue, it isunknown whether the D10S1423 234 bp allele or variants of
C10orf112 interact with APOE4 to mediate the risk of heart disease.
Northern blots of size fractionated mRNA from human hippocam-
pus interrogated with a cDNA probe consisting of C10orf112 exons 23
through 26 revealed a predominant 1.2 kb mRNA species and a rare
3.2 kb mRNA species. In comparison, the size of the predicted
C10orf112 mRNA that includes the 34 expressed exons is substantially
larger at 6.175 kb. Assuming that these 34 expressed exons are part of a
single C10orf112 gene transcript, the 1.2 and 3.2 kb mRNA species
could result from the splicing of a larger mRNA precursor that is not
detected by the northern blots shown in Figs. 3 and 4. Alternatively, the
C10orf112 gene model described in NCBI Build 35.1 may include more
than one gene. These alternatives cannot be distinguished by our data.
In silico modeling of the C10orf112 gene has continued since its
description in NCBI Build 35.1. In the current NCBI Build 36.3, the 39
predicted C10orf112 exons described in Build 35.1 have been
distributed among C10orf112 and three additional predicted loci
(LOCs). The most recent model of C10orf112 includes the previous
exons 18–26, 28, 29, and 32, encodes seven LDLa and four MAM
domains, and predicts a 2.298 kb mRNA transcript. The predicted
functional domains of the most recent C10orf112 model continue to
make it an attractive candidate for AD7. However, this revision would
place D10S1423 approximately 100 kb proximal to C10orf112, within
the adjacent gene model LOC729195. As a result, the hypothesis that
the D10S1423 234 bp allele serves as a proxy for a C10orf112 risk allele
with which it is in linkage disequilibrium would be less tenable.
It should be noted that the predicted features of the revised
C10orf112 model are not entirely consistent with the empirical data
presented in our study. Since the revised C10orf112 model includes
the sequential exons 23 through 26 identiﬁed in the previous gene
model, the cDNA probe used to interrogate the northern blots in our
study would be expected to identify the mRNA transcribed from the
revised version as well, without hybridizing to mRNA species from
adjacent genes. The observed 1.2 kb mRNA species is substantially
smaller than the 2.298 kb transcript predicted by the revised gene
model, but could arise from splicing. In contrast, the observed 3.2 kb
mRNA species is substantially larger than could be accommodated by
the revised C10orf112 model. These observations highlight the
importance of integrating gene modeling approaches with empirical
data to evaluate the predictions of the models.
The selective expression of C10orf112 mRNA in human brain tissue
is consistent with its involvement in the pathophysiology of AD, the
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expression was observed in heart tissue, and only trace (if any)
expression was observed in a wide range of other tissues besides the
placental control. Selective expression of C10orf112 was also noted
within brain regions. High levels of expression were observed in the
hippocampus, and the occipital and parietal lobes, brain regions that
undergo degeneration and manifest both senile plagues and neuroﬁ-
brillary tangles in AD. However, little or no expressionwas observed in
the frontal or temporal lobes, cortical regions that also undergo the
typical degenerative changes that occur in AD, or in the cerebellum
that is largely spared by this condition. We have previously suggested
that the heterogeneous clinical, histopathological, neurochemical, and
genetic features of AD more closely resemble a syndrome with
multiple contributing etiologies than a disease with a unitary cause
[10,11]. The expression of C10orf112 in some, but not all, brain regions
affected by AD is consistent with this hypothesis.
Materials and methods
Synthesis of cDNA from human hippocampal RNA
The cDNA ﬁrst strand product was prepared from human
hippocampus total RNA (BioChain Institute, Inc., Hayward, CA) usingTable 2
Primers used for PCR ampliﬁcation of C10orf112 predicted exons and β-actin (ACTB)
Exon forward primer
1⁎ ATGGAGCATGGATCCAAAAG
2 AAGGTCAAATGGCTTCAACG
3 TGGAATTTTACTGTGTCAAGAAGC
4 TGTGAGTGGACGTCAGAAGC
5 TTATGTATGGGTAGGCGCTAAG
6 GCGATCAAAAGTAGTGAAACTCAAC
7⁎ ACCAAGACTTTAGATTTCCTAGTACTTT
8 TTTGGACATACAACATATCAACTCAC
9 GGGACTCTTTTGAGCCAGAG
10 ACTTTGAGTCGGGTTTCTGC
11 CGTTTATTTATTTGGAGGCACAG
12 TGCAGTTTTGGTATCATTTGTC
13 TGTTTTGTCGTCAAATGCTACC
14 AAGCAAACAGCTGTGATTGG
15 GGCATTTTATGTTCATTCTGAAG
16 ACAATCAGGGCAAACAATGG
17 CACTTAACACAGGGCCAATG
18 CTTCAGTGGGAGATGGCTTC
19 CTCCCAACTCCACCAGAAAC
20 TGGAAGTTTGCAGCTTTGAG
21 TGGCTGGTACCTGTATGCTG
22 ATTGTGGGCTCAAACTGGAC
23 TTCAGAGCCAAACGTGGTATC
24 AGTGGGCGCTGTGATTTC
25 GGGCACTCACCTTAATGCAG
26 TGCTATAGGCTGGAACAAAGC
27 TGATGCGACGGCATAAATATC
28 GGCACTTCATGTATCTGGAAGC
29 AAAGGACTATCAAAAGTATGGCAAG
30 GGATGATGGGTCGGAAAAG
31 CTCCCAATCCGGTTCTATCC
32 CTGAGCTTTGTCCGGAAATC
33 GCAAATGTGATAGACATTTCCAG
34 TGGTCAGCACTTCCTGTACG
35 CTGGTGTGGTCAGTGATTGG
36 CCATCACCCTGTGAAGCTG
37 ATGGAGCTCTGGTGTGTGC
38⁎ GGCTTCGCAGAGTCGGTAAC
39 ATAGCTCCCCGGCCTGTC
ACTB GCTCGTCGTCGACAACGGCT
It was not possible to develop both forward and reverse primers within predicted exons 1 or 7
its high GC content. To assay for the expression of these predicted exons, a forward primer in
7 were paired with the reverse primer for exon 8 and the forward primer for exon 6, respectiv
39. ACTB, β-actin.the SuperScript™ III First Strand Synthesis System for RT-PCR
(Invitrogen, Carlsbad, CA) according to the manufacturer's instruc-
tions. Brieﬂy, 1 μg of total RNA was combined with 5 mM oligo(dT)20
and 1 mM dNTP mix in a total of 10 μl. The oligo(dT)20 was allowed to
anneal to the RNA poly(A) tails at 65 °C for 5 min, followed by
incubation on ice for 1 min. An equal volume of DNA synthesis
mixture was then added, consisting of 2× RT buffer, 10 mM MgCl2,
20 mM DTT, 40 U RNaseOUT™, and 200 U SuperScript™ III reverse
transcriptase. After incubation at 50 °C for 50 min to extend the
primer, the enzyme was inactivated at 85 °C for 5 min. The residual
RNA was degraded with 2 U E. coli RNase H at 37 °C for 20 min. The
ﬁrst strand synthesis product was used in subsequent PCR reactions
without further puriﬁcation.
PCR Ampliﬁcation of predicted C10orf112 exons
To conﬁrm its presence in the C10orf112 transcript, each predicted
exon was ampliﬁed in a PCR reaction using the cDNA ﬁrst strand
material prepared as described and a pair of custom synthesized
(Invitrogen, Carlsbad, CA) oligonucleotide primers as shown in Table 2,
which were designed using the software program Primer3 (http://
frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) based upon
sequence derived from the NCBI database (http://www.ncbi.nlm.nih.Reverse primer Predicted PCR
Product size(bp)
CAAGCAGCCTGAACTGAAAG 110
CAAGCAGCCTGAACTGAAAG 77
TTCATCTGTAGCATCAAATCTGC 91
TCATCATCACCTCCTTGATCC 113
CAGTCTTACTCTCAGGACACTGC 151
GATGCCAGTCTATGCTTTTCTC 84
GGAAATCTAAAGTCTTGGTAGTAAAATTG 128
AATGTCTTCAGATCTTCTGGTATTAAC 76
AGTCCTGCCGAGAGTCACAG 160
TGATCAGCTGCAGGAAAGTG 109
GACATGGGGTAGAGGCAGTG 93
GTAGATTCTCCCGCTTCTGC 160
GCTTTGTGTACTGGTCCTTGG 100
AGCCTGGTGCTCAAAATCAG 101
AAGGAAAGTATGCATCCAGGTC 103
CGATCACCACAGTCATCCAC 256
CTGCTGGAAATGTTGAGGTG 301
CAGGGTAGAGGGTGCAGTCC 75
TCTGATTTGTCAGGGCAGTC 146
GATCCACTGATGGCCTGTG 153
TGGCCCCATTCATATGTGTC 128
CCCATAACTACCTGTATTACACACC 103
GCTTGTCTTTGGCAATGCAG 151
AATTCTGGCAGCTCTCATGG 201
CAGTTCTTCTTGCACGGAATC 255
GAGAGCCAACCCCTAAAACC 157
ATGATCTGAGCTGCCAAAAG 164
GAATCTGAATGGATCCTGTGG 150
AGCTCCTCCTCCCAGGTC 153
GCTGAGATCCTTGGACCTTACTC 75
CTTCCTCTTGGGCATTCTGG 130
AGTCACAAAGAAGGTGGGATG 75
CAGGAATTCTGCTGCCAATG 200
ACACATTCCAAGGCTTGCTG 100
CACACTCTGGGGTAAAAGAGATG 160
GCACTCCATCGCATAGCAG 211
AGCTGGAAATCCATGCAGTC 88
ACAGGCCGGGGAGCTATC 303
CCACACTTTGAGGAGGGAAG 302
CAAACATGATCTGGGTCATCTTCTC 353
due to their small lengths (45 and 55 bps, respectively), or predicted exon 38 because of
exon 1 was paired with a reverse primer in exon 2; forward and reverse primers for exon
ely; and a forward primer within exon 38 was paired with a reverse primer within exon
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a positive control for PCR ampliﬁcation, and a reaction using RNA
alone (prior to ﬁrst strand synthesis) as template served as a negative
control to rule out the presence of genomic DNA contamination. Each
reaction consisted of 1 U of Platinum Taq DNA Polymerase (Invitrogen,
Carlsbad, CA), 1× buffer and 1.5 mM MgCl2, both supplied with the
enzyme, 0.2 mM of each dNTP (Amersham Pharmacia Biotech,
Piscataway, NJ), 5 pmol of each oligonucleotide primer, and 2 μl of
ﬁrst strand synthesis product, in a total volume of 25 μl. Following an
initial denaturation at 94 °C for 5 min, the fragments were ampliﬁed
by 40–50 cycles of denaturation at 94 °C for 30 s, annealing at 62 °C for
30 s, and extension at 72 °C for 1 min, followed by a ﬁnal extension at
72 °C for 7 min to assure all transcripts are full length. Bands were
resolved on 1.2% agarose (Invitrogen, Carlsbad, CA) gels, stained with
ethidium bromide (Amresco, Solon, OH), and photographed.
Northern blot analysis of human brain mRNA
Preparation of probe
The DNA probe was a PCR product spanning exons 23 through 26.
Primers 23F and 26R (Table 2) were used to amplify this region from
2 μl of cDNAﬁrst strandmaterial in a 40 cycle PCR reaction as described
above. The products of three such PCR reactions were combined and
run on a 0.75% NuSieve GTG lowmelting agarose preparative gel (FMC
BioProducts, Rockland, ME). The 946 bp band was excised with a
scalpel blade, weighed, and the DNA was recovered using the Wizard
SV Gel and PCR Clean-Up System (Promega, Madison,WI) according to
the manufacturer's instructions. The DNA was eluted in 50 μl of
nuclease free water, an aliquot was diluted 20 fold, and the
concentration was determined spectrophotometrically using a Beck-
man Instruments (Fullerton, CA) DU-640 spectrophotometer.
Preparation of blot
2mg of human brain poly A+ RNA (Stratagene, La Jolla, CA) was size
fractionated along with an RNA molecular standard (Invitrogen,
Carlsbad, CA) on a 1% agarose (Bio-Rad Laboratories, Richmond, CA)
gel containing 1× MOPS buffer (Amresco, Solon, OH) and 6.66%
formaldehyde (EMD Chemicals, Gibbstown, NJ). After two 30 min
washes in water to remove the formaldehyde, the gel was sliced
between the sample andmarker lanes. Themarker portionwas stained
with ethidiumbromide (Amresco, Solon, OH) andphotographedunder
UV exposure alongwith a ruler to permit size determinations of bands
on the subsequent northern autoradiogram.
The sample RNA was transferred from the gel to Nytran SPC
blotting membrane (Schleicher & Schuell, Inc., Keene, NH) by
drawing 20× SSC (Amresco, Solon, OH) from a sponge, through the
gel and membrane, and into Quick Draw Blotting Paper (Sigma, St.
Louis, MO) by capillary action. After transfer over night, the blot was
rinsed in 2× SSC for 5 min with gentle rocking, air dried, and then
dried under vacuum at 80 °C for 2 h. The RNAwas then crosslinked to
the membrane by exposure on a UV transilluminator (Fotodyne, New
Berlin, WI) for 1 min.
Prehybridization of blots
Prior to use, the blot membrane was wetted in 6× SSC at room
temperature for 5 min. It was then prehybridized in 5 ml of 5× SSC
(Amresco, Solon, OH), 5× Denhardt's Solution (Amresco, Solon, OH),
50% formamide (Roche Diagnostics, Indianapolis, IN), 1% SDS
(Amresco, Solon, OH), and 100 μg/ml denatured and quenched salmon
sperm DNA (Invitrogen, Carlsbad, CA) at 42 °C for 3 h in a Fisher
Scientiﬁc (Pittsburgh, PA) hybridization oven at 6 rpm.
Labeling of probe and hybridization
25 ng of gel puriﬁed exon 23–26 spanning PCR product was
labeled with 32P to a speciﬁc activity of 9.1×108 cpm/μg using the
Random Primers DNA Labeling System (Invitrogen, Carlsbad, CA) in a50 μl reaction containing 20 μM each of dATP, dTTP and dGTP, 50 μCi
of [α-32P] dCTP at 3000 Ci/mmol (PerkinElmer Life Sciences, Boston,
MA), 15 μl of Random Primers Buffer Mixture, and 3 U of Klenow
Fragment at 25 °C for 2 h. The reaction was terminated by the
addition of 5 μl of Stop Buffer. Unincorporated nucleotides were
removed using a Sephadex G-25 Quick Spin Column (Roche
Diagnostics, Indianapolis, IN). The probe was denatured at 100 °C
for 5 min and quenched on ice. The entire quenched probe was added
to the prehybridization solution, and the blot was hybridized over
night at 42 °C and 6 rpm.
Washing of blot and autoradiography
After draining off the hybridization solution, the blot was washed
twice in the hybridization tube in 25 ml of 2× SSC/0.1% SDS (Amresco,
Solon, OH) for 5 min at room temperature at 12 rpm. Two additional
5minwasheswere performed in 25ml of 0.2× SSC/0.1% SDS (Amresco,
Solon, OH) at room temperature and 12 rpm. One ﬁnal wash was
performed in 200 ml of 0.2× SSC/0.1% SDS (Amresco, Solon, OH) at
room temperature in a plastic tray with moderate rocking. The
membrane was patted dry, wrapped in Saran Wrap, and visualized by
autoradiographic exposure of Kodak (Rochester, NY) BioMax MR ﬁlm
in a Kodak X-Omatic cassette with intensifying screens at −70 °C for
exposure times that varied from over night to 6 days.
High throughput northern blot for determining human tissue-speciﬁc
expression
Prehybridization of blot
The High Throughput Human Northern Blot (BioChain Institute,
Inc., Hayward, CA) was manipulated according to the manufacturer's
instructions. The membrane was prehybridized in 3 ml of 5× SSC
(Amresco, Solon, OH), 5× Denhardt's Solution (Amresco, Solon, OH),
50% formamide (Roche Diagnostics, Indianapolis, IN), 1% SDS
(Amresco, Solon, OH), and 100 μg/ml denatured and quenched salmon
sperm DNA (Invitrogen, Carlsbad, CA) at 42 °C for 3 h in a Fisher
Scientiﬁc (Pittsburgh, PA) hybridization oven.
Labeling of probe and hybridization of blot
The DNA probe was labeled using the Random Primers DNA
Labeling System (Invitrogen, Carlsbad, CA) with minor modiﬁcations
from themanufacturer's instructions. 46 ng of gel puriﬁed exon 23–26
spanning PCR product was labeled with 32P in a 50 μl reaction
containing 20 μM dATP, 20 μM dTTP, 50 μCi each of [α-32P] dCTP and
[α-32P] dGTP at 3000 Ci/mmol (PerkinElmer Life Sciences, Boston,
MA), 15 μl of Random Primers Buffer Mixture, and 3 U of Klenow
Fragment at 25 °C for 2 h. The reactionwas terminated by the addition
of 5 μl of Stop Buffer. Unincorporated nucleotides were removed by
passing over a Sephadex G-25 Quick Spin Column (Roche Diagnostics,
Indianapolis, IN) according to the manufacturer's instructions. An
aliquot of the ﬁnal product was removed and counted in a Beckman
Instruments (Fullerton, CA) LS-1801 Liquid Scintillation Counter, and
the speciﬁc activity was determined to be 3.3×109 cpm/μg. The probe
was denatured at 100 °C for 5 min and quenched on ice. The entire
quenched probe was added to the prehybridization solution, and the
blot was hybridized over night at 42 °C and 6 rpm.
Washing of blot and autoradiography
After thoroughly draining the hybridization solution, the blot was
washed in three changes of 10 ml of 2× SSC/0.05% SDS (Amresco,
Solon, OH) at room temperature for 15 min with gentle rocking. The
majority of the remaining counts were removed by one additional
wash with 100 ml of 0.1× SSC/0.1% SDS at room temperature for
20 minwith gentle rocking. The blot was patted dry, wrapped in Saran
Wrap, and visualized by autoradiographic exposure of Kodak
(Rochester, NY) BioMax MR ﬁlm in a Kodak X-Omatic cassette with
intensifying screens at −70 °C for 72 h.
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